Worth reading
73In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
96
¥ million (amount of the upward revision to the full-year operating profit forecast)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportSecond quarter of the fiscal year ending September 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,133 million+35.8%
Operating profit¥138 million
Ordinary income¥134 million
Net income¥136 million profit attributable to owners of the parent
Gross Profit Margin73.6 %
Operating profit margin12.2 %
Selling, general and administrative expenses¥695 million
Results for the three months of the current quarter
Medical Support business revenue
¥430 million+122.8%
D2C business revenue
¥175 million-24.9%
D2C business segment profit
¥76 million+21.6%
Overseas business revenue
¥125 million
Overseas business segment profit
¥95 million
Full-year earnings forecast
Net Sales
¥2,500 million
Operating profit
¥400 million
Ordinary income
¥390 million
Net income for the current fiscal year
¥250 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Performance progressing ahead of the initial forecastBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
First-half revenue versus the initial plan
Medical Support Business
¥185 million
Overseas Operations
¥80 million
D2C Business
¥-0.3 million
First-half operating profit versus the initial plan
D2C Business
¥3 million
Medical Support Business
¥84 million
Overseas Operations
¥87 million
Other
¥90 million
Overall
¥265 million
Year-on-year operating profit
Medical Support Business
¥97 million
D2C Business
¥19 million
Other
¥95 million
Corporate Expenses
¥-21 million
New initiatives
- Product planning and development collaboration with SBC Medical Group
- Expansion of sales channels and a cross-channel strategy
- Expansion of sales channels using SBC Medical Group's clinic network
- Expansion of the affiliated-clinic network for the Medical Support business
- Collaboration in marketing efficiency and customer relationship management (CRM)
- Joint research and product and service-menu development in regenerative medicine and future technologies
Key KPIsA metric the company considers important as a management benchmark.
- Cumulative number of PDF-FD affiliated clinics796 clinics
- Annual utilization rate60.1 %
- Cumulative number of PDF-FD processing orders received19,897 Engagements
- Average processing orders received per clinic26.7 Engagements
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Average processing orders received per clinic
26.7 Engagements
Processing orders received
19,897 Engagements
Segment results
Medical Support Business
Net Sales
¥631 million
Year-on-year (%)90.4
D2C Business
Net Sales
¥376 million
Year-on-year (%)-25.2
Other
Net Sales
¥125 million
Profit
¥95 million
Financial targets
Equity ratio
Actual results65.6 %
Year-on-year change (points)0.5 %
Number of employees
99 People
As ofEnd of March 2026
Capital expenditures
¥3 millions purchases of property, plant and equipment
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Second quarter of the fiscal year ending September 2026 |
| Net Sales | ¥1,133 million (YoY +35.8%) |
| Operating profit | ¥138 million |
| Ordinary income | ¥134 million |
| Net income | ¥136 million (profit attributable to owners of the parent) |
| Gross Profit Margin | 73.6 % |
| Operating profit margin | 12.2 % |
| Selling, general and administrative expenses | ¥695 million |
| Results for the three months of the current quarter | Medical Support business revenue ¥430 million (YoY +122.8%) / D2C business revenue ¥175 million (YoY -24.9%) / D2C business segment profit ¥76 million (YoY +21.6%) / Overseas business revenue ¥125 million / Overseas business segment profit ¥95 million |
| Full-year earnings forecast | Net Sales ¥2,500 million / Operating profit ¥400 million / Ordinary income ¥390 million / Net income for the current fiscal year ¥250 million |
| Self-assessment against the plan | Performance progressing ahead of the initial forecast |
| Segment results | Medical Support Business Net Sales ¥631 million / Year-on-year (%) 90.4 / Profit Not disclosed / D2C Business Net Sales ¥376 million / Year-on-year (%) -25.2 / Profit Not disclosed / Other Net Sales ¥125 million / Year on year against the same period last year Not disclosed / Profit ¥95 million / Corporate Expenses Not disclosed |
| Breakdown of Factors Affecting the Change | First-half revenue versus the initial plan Medical Support Business ¥185 million / Overseas Operations ¥80 million / D2C Business ¥-0.3 million / First-half operating profit versus the initial plan D2C Business ¥3 million / Medical Support Business ¥84 million / Overseas Operations ¥87 million / Other ¥90 million / Overall ¥265 million / Year-on-year operating profit Medical Support Business ¥97 million / D2C Business ¥19 million / Other ¥95 million / Corporate Expenses ¥-21 million |
| Key KPIs | Indicator name Cumulative number of PDF-FD affiliated clinics / Value 796 clinics / Year on year against the same period last year Not disclosed, Indicator name Annual utilization rate / Value 60.1 % / Year on year against the same period last year Not disclosed, Indicator name Cumulative number of PDF-FD processing orders received / Value 19,897 Engagements / Year on year against the same period last year Not disclosed, Indicator name Average processing orders received per clinic / Value 26.7 Engagements / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | Average processing orders received per clinic 26.7 Engagements / Processing orders received 19,897 Engagements |
| Number of employees | 99 People |
| Financial targets | Equity ratio Actual results 65.6 % / Year-on-year change (points) 0.5 % / Target Not disclosed |
| Capital expenditures | ¥3 millions (purchases of property, plant and equipment) |
| New initiatives | Product planning and development collaboration with SBC Medical Group, Expansion of sales channels and a cross-channel strategy, Expansion of sales channels using SBC Medical Group's clinic network, Expansion of the affiliated-clinic network for the Medical Support business, Collaboration in marketing efficiency and customer relationship management (CRM), Joint research and product and service-menu development in regenerative medicine and future technologies |
Items this document does not state (11)
Progress against full-year forecastNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Performance was progressing ahead of the initial forecast as of the interim results. The main factors behind the revision were the realization of some business synergies with SBC Medical Group, the sharp growth of the Medical Support business and the rapid expansion of the overseas business. First-half results were attributed to strong business progress and cost control.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.